MAP2K1 and malignant colon neoplasm: In a recent study, MAP855 was successfully used to inhibit ERK activation in MEK1 V211D-mutant colon cancer cells that were already resistant to binimetinib and MAP855 treatment decreased tumor growth by 30% through reduction of proliferation and induction of apoptosis in the in vivo PDX model of the original patient tumor [29].